Opinion: Purple Book Patent Listings Are Only a First Step
May 8, 2021
By: Ted Mathias and Aaron Savit, PhD
The Center for Biosimilars
Axinn partners Ted Mathias and associate Aaron Savit authored The Center for Biosimilars article, "Opinion: Purple Book Patent Listings Are Only a First Step."
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Informa 34th Annual Advanced EU Brussels Conference
Speaking Engagement
Antitrust
Kisaco Research Pharma and Biotech Patent Litigation Summit 2025
Speaking Engagement
Intellectual Property
GCR Live: Women in Antitrust 2025
Speaking Engagement
Antitrust
Global Legal Group Global Class Actions Symposium 2025
Speaking Engagement
Litigation & Trials
ITCTLA Mock Hearing Program 2025
Speaking Engagement
Intellectual Property
ALM General Counsel Conference East 2025
Speaking Engagement
Antitrust
NAPABA Convention 2025
Sponsorship
Antitrust
IBA Annual Conference 2025
Speaking Engagement
Antitrust
Axinn Advises Thermo Fisher Scientific in Strategic Acquisition of Clario Holdings Inc.
Deals & Cases
Antitrust
Axinn Partners Ranked in the 2026 Edition of Benchmark Litigation
Awards & Recognitions
Litigation & Trials

